FIELD: biotechnology.
SUBSTANCE: described is a pharmaceutical formulation for stabilizing bevacizumab, which contains bevacizumab, a buffer, a stabilizer, and a surfactant. In one embodiment, composition contains 10 mM of a buffer based on histidine hydrochloride and sodium acetate, 45 mg/ml of sorbitol and 0.2 mg/ml of Tween-80 with pH value of 5.3.
EFFECT: invention extends the range of agents for bevacizumab stabilization.
10 cl, 8 dwg, 28 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY COMPOSITION | 2015 |
|
RU2743681C2 |
| STABLE LIQUID COMPOSITION OF FUSED PROTEIN WITH DOMAIN Fc IgG | 2016 |
|
RU2688679C1 |
| STABLE LIQUID PHARMACEUTICAL PREPARATIONS OF FUSED PROTEIN TNFR: Fc | 2012 |
|
RU2614257C2 |
| HUMAN PARATHYROID HORMONE (PTH) FORMULATIONS AND METHODS FOR PREPARING THEREOF | 2020 |
|
RU2820316C1 |
| ANTIBODY COMPOSITIONS | 2010 |
|
RU2548772C2 |
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ADALIMUMAB | 2014 |
|
RU2664736C2 |
| STABLE AQUEOUS COMPOSITIONS BASED ON ANTIBODIES | 2014 |
|
RU2763787C2 |
| STABLE LIQUID PHARMACEUTICAL COMPOSITION | 2018 |
|
RU2773747C2 |
| PHARMACEUTICAL FORMULA CONTAINING HUMAN ANTI-TSLP ANTIBODY | 2016 |
|
RU2794148C2 |
